{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:27:36Z","timestamp":1762432056495,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ijrobp.2021.04.013","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T02:25:47Z","timestamp":1619231147000},"page":"732-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial"],"prefix":"10.1016","volume":"111","author":[{"given":"Abdenour","family":"Nabid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Vigneault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thu","family":"Van Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vavassis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Andr\u00e9","family":"Brassard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Bahoric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Redouane","family":"Bettahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"National Comprehensive Cancer Network, Guidelines Prostate Cancer Version 1","author":"Mohler","key":"10.1016\/j.ijrobp.2021.04.013_bib0001"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0002","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","article-title":"Time trends and local variation in primary treatment of localized prostate cancer","volume":"28","author":"Cooperberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0003","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15083","article-title":"Effect of androgen deprivation on long-term outcomes of intermediate-risk prostate cancer stratified as favorable or unfavorable. A secondary analysis of the RTOG 9408 randomized clinical trial","volume":"3","author":"Zumsteg","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0006","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"JR Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0008","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2012.06.030","article-title":"Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?","volume":"85","author":"Castle","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2147\/OTT.S102327","article-title":"Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?","volume":"9","author":"Shakespeare","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0010","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/cncr.29420","article-title":"Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease","volume":"121","author":"Keane","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijrobp.2018.08.030","article-title":"Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy","volume":"103","author":"Berlin","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0013","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate and high-risk localized prostate cancer: Results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.04.013_bib0014","first-page":"289","article-title":"Androgen suppression and radiation vs. radiation alone for prostate cancer: A randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621003734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621003734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:53:06Z","timestamp":1759744386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621003734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0360301621003734"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}